Roveril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roveril

Roveril is formally defined as a Fixed-Dose Combination medicine, which integrates two distinct therapeutic agents into a single unit to address both systemic and local symptoms of upper respiratory illnesses. It is classified as an Upper Respiratory Combination drug, primarily targeting the discomfort of common cold and flu.

Property Description
Active Ingredients Ibuprofen, Pseudoephedrine Hydrochloride
Form Tablet, Film-coated tablet, Liquid-filled capsule (Oral)
Pharmacological Class Analgesic and Decongestant Combination
Common Use Symptomatic relief of cold and flu
Origin Synthetic

What Type of Medicine is Roveril and What is its Composition?

Roveril's identity rests on its dual composition, which pairs an analgesic with a decongestant. The formulation contains Ibuprofen, categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID), and Pseudoephedrine Hydrochloride, classified as a Sympathomimetic Amine. Both chemical substances are synthetic in origin and are fixed in predetermined quantities across available dosage forms, which include the tablet and liquid-filled capsule. This pairing is clinically recognized for its efficacy in targeting the complex symptom set of the common cold, providing a specific and measurable therapeutic profile based on the actions of each pharmacological class.


What is the Purpose of Roveril's Combination Formula?

The general purpose of Roveril’s formula is to provide more comprehensive symptomatic relief compared to using single-ingredient medications. This Analgesic and Decongestant Combination lessens overall physical discomfort while directly addressing obstructed breathing. The Ibuprofen component provides a systemic benefit by acting as an antipyretic (fever reducer) and relieving minor body aches and pains. This pairing of an analgesic with a decongestant is utilized to improve patient well-being during a cold. Concurrently, the Pseudoephedrine component addresses the primary source of localized distress by inducing vasoconstriction, which works to shrink the swollen mucous membranes and relieve the feeling of nasal congestion and sinus pressure.

What side effects are possible with Roveril?

Safety Profile and Adverse Reactions

The medicine's official safety profile is a composite of the risks associated with its two active components: Ibuprofen (a Nonsteroidal Anti-inflammatory Drug or NSAID) and Pseudoephedrine Hydrochloride (a Sympathomimetic Amine). Adverse reactions are formally documented and categorized by frequency and the body's affected System-Organ Class (SOC) in government regulatory documents.

Classification Examples of Officially Documented Effects
Common Gastrointestinal disturbances (such as nausea, dyspepsia), headache, dizziness, insomnia, and nervousness.
Uncommon to Rare Hypersensitivity reactions (rash, urticaria), severe blood disorders, and fluid retention.

Serious Adverse Reactions and Regulatory Constraints

The regulatory labeling highlights specific, serious adverse events associated with the components. These are generally rare but clinically significant:

  • Cardiovascular and Cerebrovascular Risk: Documented risk of serious arterial thrombotic events, including Myocardial Infarction and Stroke, which may increase with prolonged use.
  • Gastrointestinal Risk: Potential for serious gastrointestinal adverse events, including bleeding, ulceration, and perforation.
  • Neurovascular Risk: The decongestant component is associated with risks of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS).

Population-Specific Safety Considerations are defined, with official warnings for Older Adults (increased risk of GI and renal events) and specific constraints regarding use during the Third Trimester of Pregnancy. Furthermore, the medicine is contraindicated in conditions such as severe, uncontrolled hypertension, severe coronary artery disease, or recent use of a Monoamine Oxidase Inhibitor (MAOI).

Overdose and Emergency Response

An overdose of this fixed-dose combination medicine may present with documented signs reflecting the toxicity of both active components. Manifestations associated with acute toxicity include severe gastrointestinal findings such as bloody or black stools and vomiting blood, alongside reports of severe stomach pain. Neurological and cardiovascular signs may include nervousness, sleeplessness, dizziness, chest pain, and slurred speech.

When to seek urgent help Regulatory documents explicitly mandate that in case of a suspected overdose, the individual must Get Medical Help Right Away and Contact a Poison Control Center Right Away. This immediate action is required due to the documented potential for severe and life-threatening outcomes.

Severity and Management The official prescribing information indicates that severe cardiovascular events, including Heart Attack, Heart Failure, and Stroke, are documented risks that can be fatal. As No Specific Antidote is known, the required management approach is strictly defined as Symptomatic and Supportive Treatment. Hospital monitoring is necessary, focusing on continuous cardiovascular observation and assessment of renal and hepatic function. This procedural focus underscores the gravity of an overdose scenario as defined by regulatory authorities.

Therapeutic Uses of Roveril

The Ibuprofen/Pseudoephedrine combination is generally used to provide symptomatic relief across multiple domains associated with upper respiratory illnesses, most commonly the common cold and influenza (flu). The combination is commonly used when short-term symptomatic assistance is needed during episodes where symptoms create noticeable physiological strain.

The combination is relevant for easing symptoms such as headache, fever, sinus pressure, nasal congestion, and minor body aches and pains. This medication is applicable within clinical settings that involve acute or disruptive symptom patterns.

“The primary goal of this combination product is to provide supportive relief that helps patients cope more steadily with difficult episodes where both pain and obstruction are present.”

Applied in contexts where additional symptomatic support is needed, the combination helps ease the overall symptom burden. It provides support for symptoms related to systemic imbalance (fever, aches) and addresses symptoms that interfere with daily functioning (nasal and sinus blockage), which contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Sinus Congestion

The product assists with maintaining functional stability when symptoms interfere with daily functioning like nasal congestion and sinus pressure, which is relevant for easing discomfort when breathing and sleeping are affected by inflammation.

Regulatory References

  1. NIH DailyMed product labeling

Eligibility and Restrictions for Use

Eligibility Scope

Roveril, a combination of Ibuprofen (NSAID) and Pseudoephedrine (decongestant), is officially permitted for use by adults and adolescents aged 12 years and over. Use is generally not recommended in children under 12 years of age.


Contraindicated Populations

Regulatory labeling establishes several populations who must not use this medicine. This absolute prohibition applies to patients with:

  • A known allergy or severe reaction to Ibuprofen, Pseudoephedrine, or any other NSAID (Nonsteroidal Anti-inflammatory Drug), including aspirin.
  • Concurrent use of, or use within the last 14 days (2 weeks) of, a Monoamine Oxidase Inhibitor (MAOI) drug.
  • Severe or uncontrolled hypertension, severe coronary artery disease, or severe kidney failure.
  • A history of active peptic ulcers or recurrent gastrointestinal ulceration.
  • Use for pain relief right before or right after heart bypass surgery (CABG).
  • Use during the last three months of pregnancy.

Condition-Based Restrictions

Patients with certain pre-existing conditions that are not severe or uncontrolled must ask a health professional before use. These conditions include less severe high blood pressure, heart disease, liver disease, kidney disease, diabetes, thyroid disease, or glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Officially Documented Interaction Requirements
Prohibited Combinations Monoamine Oxidase Inhibitors (MAOIs) and Ergot Derivatives are formally contraindicated. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is mandated to be avoided.
Timing Restriction The product must not be used with or within two weeks of stopping a Monoamine Oxidase Inhibitor drug.
Exposure Alterations The Ibuprofen component may increase the plasma concentrations of Lithium and Methotrexate by reducing their official clearance rate.
Pharmacodynamic Risk Officially increases the risk of gastrointestinal bleeding when co-administered with Anticoagulants or Oral Corticosteroids. Pseudoephedrine may counteract the effects of Antihypertensive Agents.

The official regulatory profile is structured around the significant interaction risks presented by its two active agents. The Pseudoephedrine component requires formal restrictions, including the mandated avoidance of other Sympathomimetic Agents or Decongestants, and the strict contraindication with MAOIs due to the risk of acute hypertensive effects. The Ibuprofen component establishes the need to avoid alcohol (ethanol), as official labeling states this combination increases the risk of gastrointestinal bleeding. Additionally, Ibuprofen is documented to competitively inhibit the anti-platelet effect of Low-Dose Aspirin. The profile specifically notes that the interaction risk with Methotrexate is heightened in patients with reduced renal function.

Mechanism of Action

Modulating Inflammatory Mediators via Enzyme Inhibition

This domain is driven by Ibuprofen, which acts as a non-selective inhibitor of Cyclooxygenase enzymes ( COX-1 and COX-2). By blocking these enzymes, the action interrupts the conversion of arachidonic acid, leading to a reduction in prostaglandin concentration within the arachidonic acid cascade. This mechanistic action modulates central processes like hypothalamic thermoregulation and peripheral processes like nociceptor excitation threshold.


Localized Modulation of Nasal Vascular Tone

This domain is defined by the action of Pseudoephedrine HCl, which is an agonist of alpha-1 (alpha1) adrenergic receptors on the smooth muscle of blood vessels in the nasal passages. This interaction is part of the autonomic pathway governing localized microvascular smooth muscle contraction. The resulting vasoconstriction reduces blood flow and volume in the nasal mucosa, initiating a physical reduction of interstitial fluid accumulation and tissue volume.

Dosage and Administration Information

How to Use Roveril

Roveril (Ibuprofen / Pseudoephedrine Hydrochloride) is officially administered via the oral route, available in fixed-dose units such as the tablet and liquid-filled capsule. The usage pattern is strictly defined by guidelines concerning dose, frequency, and maximum duration, and is not intended for long-term use.


Official Administration Guidelines

The protocol mandates taking one to two units by mouth, providing a single dose of 200–400 mg Ibuprofen and 30–60 mg Pseudoephedrine Hydrochloride. The unit must be swallowed whole with water and may be taken with food or milk to help minimize potential gastric discomfort. The official administration schedule requires that doses be separated by a minimum of four hours and allows for administration up to every 4 to 6 hours as needed.


Usage Constraints and Duration

Strict adherence to the maximum allowed intake is required: the total administration must not exceed 6 units (1200 mg Ibuprofen / 180 mg Pseudoephedrine) in any 24-hour period. Use is constrained to a short-term maximum of seven consecutive days for symptomatic relief. The combination is not intended for use in patients under 12 years of age. If a dose is missed, the next unit should be taken at the next scheduled time, maintaining the minimum four-hour interval between doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Roveril

This section provides an overview of the types of clinical studies and aggregated research that describe the Ibuprofen/Pseudoephedrine combination, according to regulatory and scientific bodies.

Evidence for Symptomatic Relief in Upper Respiratory Illnesses

The core evidence is derived from short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that aggregated trial data. Research was conducted on symptomatic relief in conditions involving periods of heightened symptoms, such as the common cold and influenza. The key focus was on patient-reported outcomes describing perceived discomfort, including headache, minor body aches, nasal congestion, and sinus pressure.

Studies monitored specific outcomes related to individual symptoms in observed populations, generally consisting of adults and adolescents. Research describes patterns related to symptom intensity or variability that were monitored during the trials. The findings primarily describe group patterns, and research does not determine whether an individual will experience similar outcomes.

Study Landscape and Comparative Research

The clinical evaluation of this combination product was evaluated in research comparing its use against a placebo (an inactive substance) as well as against the two active ingredients when used alone. This approach formed part of the broader evidence base, examining short-term symptom patterns. Research also included observational settings exploring daily-life functioning in individuals using this combination.

Long-Term Studies and Follow-up Duration

The research was primarily based on short-term follow-up durations, which aligned with the study's focus on acute symptom patterns. Consequently, there is limited information for long-term outcomes, and the long-term effects are not fully established. There are no extended-duration trials designed to describe the effects of repeated or prolonged use of the combination.

What is Still Uncertain About Roveril

The existing body of evidence highlights what is known—and what is still uncertain. One main uncertainty is the lack of information regarding long-term outcomes because follow-up durations were limited. Subgroup findings are also uncertain; the evidence quality varies across studies when attempting to determine patterns in specific, narrow patient categories. Data for certain groups, such as older adults or individuals with pre-existing conditions, remain insufficient.

Key Studies & References

  1. Ibuprofen and pseudoephedrine (DailyMed product label)
  2. Ibuprofen/Pseudoephedrine Overview

Frequently Asked Questions (FAQ)

Common questions about Roveril (FAQ)

Q: Can Roveril affect my sleep patterns?

A: Yes, official regulatory documents indicate that side effects can include 'insomnia' or other sleep-related issues. This is often linked to the decongestant component of the medicine. Awareness of potential effects is part of using the product.


Q: What are the most common mild side effects of Roveril?

A: According to the official product information, common side effects include gastrointestinal discomfort such as stomach upset or nausea, headache, dizziness, nervousness, and issues with sleep. These effects are generally mild and documented in regulatory literature.


Q: What should I do if a minor side effect of Roveril doesn't go away?

A: Official labeling advises consulting a healthcare professional if symptoms continue or get worse, or if new symptoms appear after using the product. This consultation allows for proper evaluation of the ongoing symptom.


Q: Is it normal to feel a bit nauseous when first starting Roveril?

A: Nausea is listed as a common side effect of this medication. The product label states that taking the medicine with food or milk is suggested if stomach upset occurs. If the nausea or stomach pain becomes severe or lasts, official guidance advises stopping use.


Q: Can I drive a car while taking Roveril?

A: The medicine is associated with potential side effects like dizziness and drowsiness. Due to these potential effects, caution is generally advised when performing tasks that require full alertness, such as driving or operating machinery.


Q: Is there a list of serious but rare side effects of Roveril I should be aware of?

A: Yes, official warnings document rare but clinically significant risks. These include the potential for serious arterial thrombotic events like heart attack and stroke, severe gastrointestinal issues like bleeding or ulceration, and rare but severe allergic reactions.


Q: Are there different strengths or formulations of Roveril available?

A: The fixed-dose combination of Ibuprofen and Pseudoephedrine is manufactured in different regulated forms, which typically include tablets, caplets, and liquid-filled capsules. Official product information confirms these various forms and approved strengths are available.


Q: Does alcohol consumption affect the safety or effectiveness of Roveril?

A: Official labeling contains a warning about alcohol consumption. Combining the Ibuprofen component with alcohol (specifically three or more drinks per day) significantly increases the risk of severe stomach bleeding.


Q: Can Roveril cause a dry mouth, and is there a way to manage it?

A: Dry mouth is a possible side effect associated with the decongestant component (Pseudoephedrine). Official drug labels focus on safety and efficacy, and typically do not provide self-management strategies for side effects.


Q: Does Roveril affect blood pressure or heart rate?

A: The decongestant component can affect the cardiovascular system, which is why the medicine is contraindicated in severe, uncontrolled high blood pressure. Official warnings indicate that individuals with pre-existing high blood pressure or heart disease are advised to discuss use with a health professional.


Q: Can Roveril be crushed or split if a person has trouble swallowing pills?

A: Official administration guidelines for this type of product generally state that the tablets or capsules must be swallowed whole with water. There is typically no official regulatory guidance that permits the splitting or crushing of this fixed-dose combination.


Q: Why do some people experience initial anxiety when starting Roveril?

A: The regulatory profile includes 'nervousness' and 'anxiety' as possible side effects. These effects are often associated with the Sympathomimetic Amine (Pseudoephedrine) component, which can sometimes cause central nervous system stimulation.


Q: Does taking Roveril at a specific time of day matter?

A: The official directions focus on the minimum time interval required between doses, which is typically four to six hours. Given the risk of sleep problems (insomnia), avoidance of taking a dose close to bedtime may be considered.


Q: What if I accidentally take two doses of Roveril close together?

A: Official warnings state that a person should not exceed the maximum recommended dose in any 24-hour period. In the event of an overdose, the labeling instructs contacting a Poison Control Center or seeking immediate professional medical help.


Q: How long does Roveril stay in your system after stopping it?

A: The elimination of drugs is measured by their half-life. For the ibuprofen component, the half-life is approximately 1.9 to 2.2 hours. A half-life defines the time required for the body to eliminate half of the drug.


Q: Who exactly is considered high-risk for taking Roveril?

A: Official warnings identify high-risk groups, including older adults, individuals with a history of stomach ulcers or bleeding, and patients who are taking blood thinners. Specific pre-existing conditions like severe high blood pressure also place a person in a high-risk category where use is contraindicated.


Q: Are there any known allergies to the inactive ingredients in Roveril?

A: The Allergy Alert section of regulatory labels focuses primarily on known allergies to the active ingredients and other related NSAIDs. The inactive ingredients are listed on the packaging, but specific allergy warnings for these ingredients are generally not detailed in the main regulatory labeling.


Q: How does the body eliminate Roveril?

A: According to pharmacokinetic data, both active ingredients are primarily broken down in the liver into inactive compounds. They are then eliminated from the body, mostly through the kidneys, which occurs relatively rapidly.

How should Roveril be stored and disposed of?

Roveril (Ibuprofen/Pseudoephedrine HCl) must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Official Storage Conditions

Requirement Specifics
Temperature Store at Controlled Room Temperature, between 20 C to 25 C (68 F to 77 F).
Protection Keep the product in the original container and tightly closed. Protect from moisture and excessive heat (do not store above 30 C).
Prohibited Environment Do not refrigerate and do not freeze the oral tablets or capsules.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Roveril must be disposed of via a medicine take-back program or according to local government regulations. The medication should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roveril found in:

A-Z Index: